IntraBio files the first-ever FDA application for an A-T therapy. Analyse the Phase III evidence, regulatory pathway, and what approval would mean.
ImmunityBio’s first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Myriad Genetics secures FDA approval for MyChoice CDx in ovarian cancer. Discover how HRD testing could reshape PARP inhibitor treatment decisions.